Unlock instant, AI-driven research and patent intelligence for your innovation.

Beta-sheet breaker peptide analogs that inhibit beta-pleated sheet formation in amyloid beta-peptide

a technology of amyloid beta-peptide and amyloid beta-peptide, which is applied in the direction of peptide/protein ingredients, peptide sources, biocide, etc., can solve the problems of neurodegenerative problems, loss of short-term memory, disorientation, and impairment of judgment and reasoning, and the development of peptide drugs is strongly limited

Inactive Publication Date: 2006-03-30
AXONYX INC
View PDF47 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The modified peptides demonstrate improved bioavailability and stability, effectively inhibiting amyloid formation and dissolving preformed deposits, thereby reversing associated cerebral histologic damage and preventing neuronal death, offering a potential therapeutic approach for protein conformational diseases.

Problems solved by technology

Alzheimer's disease (AD) is a devastating neurodegenerative problem characterized by loss of short-term memory, disorientation, and impairment of judgment and reasoning.
However, the development of peptide drugs is strongly limited by their lack of oral bioavailability and their short duration of action resulting from enzymatic degradation in vivo (Fauchere and Thurieau, Adv.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Beta-sheet breaker peptide analogs that inhibit beta-pleated sheet formation in amyloid beta-peptide
  • Beta-sheet breaker peptide analogs that inhibit beta-pleated sheet formation in amyloid beta-peptide
  • Beta-sheet breaker peptide analogs that inhibit beta-pleated sheet formation in amyloid beta-peptide

Examples

Experimental program
Comparison scheme
Effect test

examples

[0110] One of the major drawbacks for the use of peptides as drugs is their rapid proteolytic degradation in biological fluids and tissues. In in vitro experiments, iAβ5, (Seq. LPFFD, also depicted as Leu Pro Phe Phe Asp herein) degraded very quickly in vitro after incubation with fresh human plasma. As shown in FIG. 4a, fifty percent of the peptide iAβ5 disappeared in approximately five minutes in the presence of plasma. Since it was not possible to identify any metabolic fragments as a result of the proteolytic digestion, it seems likely that the degradation is mainly done by unspecific exopeptidases. This conclusion is supported by the finding that protection of amino- and carboxy-terminus of the peptide by acetylation and amidation, respectively, (to form Ac-iAβ5-Am—also depicted as Ac-Leu Pro Phe Phe Asp-Am herein) dramatically increases the stability of the peptide in vitro. As shown in FIG. 4b, the end-protected modified peptide of the present invention (Ac-iAβ5-Am) remained ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
volumeaaaaaaaaaa
pHaaaaaaaaaa
Login to View More

Abstract

The present invention provides peptide analogs and peptide mimetics that inhibit pleated sheet formation in amyloid β-peptide, pharmaceutical compositions thereof and their therapeutic use. The inhibitory peptides possess activity as inhibitors in the formation of amyloid-like deposits and are useful in the treatment of Alzheimer's Disease.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a divisional of U.S. patent application Ser. No. 10 / 726,366, filed Dec. 3, 2003, which is a continuation of U.S. patent application Ser. No. 09 / 706,540, filed Nov. 4, 2000, now U.S. Pat. No. 6,689,753, issued Feb. 10, 2004, which claims the benefit of U.S. Provisional Application No. 60 / 163,911, filed Nov. 5, 1999, the entirety of each of which is incorporated by reference.FIELD OF THE INVENTION [0002] The present invention relates to peptide analogs and peptide mimetics of β-sheet breaker peptides suitable for in vivo use in treating mammals with protein conformational diseases such as Alzheimer's and prion disease. More particularly, the present invention is directed to novel peptide analogs and mimetics, pharmaceutical compositions containing one or a mixture of such peptide analogs and mimetics, and methods for preventing, treating, or detecting disorders or diseases associated with abnormal protein folding into ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/70A01N43/04A61K38/00C07C229/34C07K5/02C07K14/47
CPCA61K38/00C07C229/34C07K14/4711C07K5/0207C07K14/47C07C2101/08C07C2601/08
Inventor SOTO-JARA, CLAUDIO
Owner AXONYX INC